Skip to main content
      Project from my group & rheum-bound resident Mary Peng!

      As expected, ischemic vision loss for GCA compared to PMR

      Mike Putman EBRheum

      2 weeks ago
      Project from my group & rheum-bound resident Mary Peng! As expected, ischemic vision loss for GCA compared to PMR (HR 5.4) and gen pop (HR 5.6) 😬 NO difference for PMR vs gen pop (aHR 1.10, 95% CI 0.86–1.41) Reassuring for pts w/PMR! #ACR25 @RheumNow Abstr#0753 #ACRBest https://t.co/HKzc7OOzmP
      Only 32% of RA pts were satisfied with current txs. In a discrete choice experiment of 354 US pts, many preferred a vagu

      Jiha Lee JihaRheum

      2 weeks ago
      Only 32% of RA pts were satisfied with current txs. In a discrete choice experiment of 354 US pts, many preferred a vagus nerve stimulator over another biologic/JAKi, especially those with prior tx failures. Cost, function, and fatigue drove preferences. @RheumNow #ACR25 A#0370
      Icotrokinra, a first-in-class targeted oral peptide IL-23R inhibitor, cleared scalp (66%), genital (77%), and overall sk

      Antoni Chan MD (Prof) synovialjoints

      2 weeks ago
      Icotrokinra, a first-in-class targeted oral peptide IL-23R inhibitor, cleared scalp (66%), genital (77%), and overall skin (57%) PsO vs placebo at Week 16. Basket trial design enabled targeted evaluation. Safety profile favorable. Abstract 0555 @RheumNow #ACR25
      Phenotypes of GCA:

      Pt dx by PET compared to TA biopsy were:
      - younger
      -longer disease before dx
      -more frequent extrem

      Brian Jaros, MD Dr_Brian_MD

      2 weeks ago
      Phenotypes of GCA: Pt dx by PET compared to TA biopsy were: - younger -longer disease before dx -more frequent extremity claudication (still overall low) -less cranial / TA sx @RheumNow #ACR25 Abstract 0759 https://t.co/ilwa3eYmRq
      Avacopan in the real world: we need to be braver
      If we want to get steroid-sparing benefit in AAV, we need to trust it

      David Liew drdavidliew

      2 weeks ago
      Avacopan in the real world: we need to be braver If we want to get steroid-sparing benefit in AAV, we need to trust it claims data shows modest PNL reduction with avacopan some manifestations are harder to taper in, but others we just need to be bolder #ACR25 ABST0726 @RheumNow https://t.co/51nGdpR2db
      Can the blood reflect what’s happening in the joint? In early RA, 11 synovial proteins mirrored serum levels, forming

      Jiha Lee JihaRheum

      2 weeks ago
      Can the blood reflect what’s happening in the joint? In early RA, 11 synovial proteins mirrored serum levels, forming an inflammatory signature linked to disease activity and csDMARD response. High-signature pts had stronger treatment responses (AUC>0.8) @RheumNow #ACR25 A#0070
      A systematic review by Dr. SRamiro et al evaluated efficacy of b/tsDMARDs on peripheral axSpA

      Majority on bDMARDs (TNFi

      sheila RHEUMarampa

      2 weeks ago
      A systematic review by Dr. SRamiro et al evaluated efficacy of b/tsDMARDs on peripheral axSpA Majority on bDMARDs (TNFi, n=24; IL-17, n=13) Most of the SMDs were small --> b/tsDMARDs showed small to moderate effects on peripheral arthritis & enthesitis. #ACR25 @RheumNow Abs0588 https://t.co/yGXcqhZ1Uv
      Cool study using vasculitis patient-powered reserach network (VPPRN)

      "SNOT-22" tool captures sinonasal symptoms; associ

      Mike Putman EBRheum

      2 weeks ago
      Cool study using vasculitis patient-powered reserach network (VPPRN) "SNOT-22" tool captures sinonasal symptoms; associated with disease activity (expected) but also worse among pts even in remission Very important impacter of QOL in AAV #ACR25 @RheumNow Abstr0725 https://t.co/NQBW8VnYFS
      Miller et al. Fibrinogen for GCA diagnosis and flare identification. Similar to ESR/CRP in diagnosis. For flares, lower

      Richard Conway RichardPAConway

      2 weeks ago
      Miller et al. Fibrinogen for GCA diagnosis and flare identification. Similar to ESR/CRP in diagnosis. For flares, lower sensitivity (79%) but better specificity (96%) @RheumNow #ACR25 Abstr#750 https://t.co/SIkAkEeYh1
      ASAS recommends standardised reporting for 20 key outcomes in axSpA trials, 10 for all studies, 10 specific to DMARD tri

      Antoni Chan MD (Prof) synovialjoints

      2 weeks ago
      ASAS recommends standardised reporting for 20 key outcomes in axSpA trials, 10 for all studies, 10 specific to DMARD trials. Formats include mean (±SD), mean change, and categorical thresholds for ASDAS, ASAS-HI, and extra-musculoskeletal manifestations. 85% of ASAS members https://t.co/VQwPaTRIOl
      Poster evaluating representation in trials of AAV and GCA

      Results mirror those observed in other fields; need to keep a

      Mike Putman EBRheum

      2 weeks ago
      Poster evaluating representation in trials of AAV and GCA Results mirror those observed in other fields; need to keep advocating for trials in all populations! #ACR25 @RheumNow Abstr#0720 https://t.co/gDj5IQMJOc
      #ACR25 Abstr#776 2-Year SELECT-GCA RCT showed that #GCA patients receiving continuous UPA15 to 2-yr maintained their rem

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 weeks ago
      #ACR25 Abstr#776 2-Year SELECT-GCA RCT showed that #GCA patients receiving continuous UPA15 to 2-yr maintained their remission (69%) vs those who switched to PBO after in remission for ≥24 weeks (29%). Lower serious infection but higher herpes zoster in UPA15. One VTE @RheumNow https://t.co/FCTNqCVxiZ
      Fascinating: tDR-1, a microbial sRNA, appears protective for RA in at risk ACPA+ pts:

      - tDR-1 higher = less develop RA

      David Liew drdavidliew

      2 weeks ago
      Fascinating: tDR-1, a microbial sRNA, appears protective for RA in at risk ACPA+ pts: - tDR-1 higher = less develop RA - can predict seropos RA development - in vitro type 1 IFN mapping checks out Useful in itself, but importantly: why does it happen? #ACR25 ABST0775 @RheumNow https://t.co/ep99dNAzFV
      No seasonal pattern in GCA!

      We have also looked at this in our data and similarly found no trends

      It sure feels like

      Mike Putman EBRheum

      2 weeks ago
      No seasonal pattern in GCA! We have also looked at this in our data and similarly found no trends It sure feels like GCA comes in waves, but data does not bear this out #ACR25 @RheumNow Abstr#0754 https://t.co/4y2elYmCRT
      Lindberg et al. Nationwide case-control study in Sweden. Big increase in risk of DVT/PE in AAV, most marked early after

      Richard Conway RichardPAConway

      2 weeks ago
      Lindberg et al. Nationwide case-control study in Sweden. Big increase in risk of DVT/PE in AAV, most marked early after diagnosis @RheumNow #ACR25 Abstr#718 https://t.co/FpDcbX15hm
      ×